Previous 10 | Next 10 |
VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients VASCEPA in REDUCE-IT® cardiovascular outcomes study achieved statistical significance for primary and secondary endpoints at predef...
Aimmune Therapeutics (NASDAQ: AIMT ) +171% on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) announces positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoiet...
An 80-subject Phase 4 clinical trial, EVAPORATE , evaluating Amarin's (NASDAQ: AMRN ) Vascepa (icosapent ethyl) in patients with elevated triglycerides (200 - 499 mg/dL) and coronary atherosclerosis on statin therapy met the primary endpoin t demonstrating a statistically significant red...
Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA Significant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides further insight to potential mechanisms of action VASCEPA is the first and only agent...
Matinas BioPharma (NYSEMKT: MTNB ) has completed enrollment in an open-label 100-subject Phase 2 clinical trial, ENHANCE-IT , comparing the effectiveness of lead candidate MAT9001 to Amarin's (NASDAQ: AMRN ) Vascepa (icosapent ethyl) in reducing triglyceride levels and other lipid m...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, was featured in an editorial by Financial News Media. The piece, titled “Global Brain Tumor The...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, was featured in an editorial by Financial News Media. The piece, titled “Global Brain Tumor The...
August 27, 2020 Palm Beach, FL – August 27, 2020 – Across the globe, there has been an increasing prevalence on brain cancer over the past few years and the industry is expected to grow as a result. The major driving factor responsible for the growth of brain tumors ...
Immunic (NASDAQ: IMUX ) is up 16.2% after hours - rebounding from a regular-session decline of 5.7% - after Piper Sandler named it one of its best ideas for biotech "bargain shopping." More news on: Immunic, Inc., Lumos Pharma, Inc., Amarin Corporation plc, Healthcare stocks news, News...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...